- Home
- EWTX vs PGRE Comparison
EWTX vs PGRE Comparison
Compare EWTX & PGRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- PGRE
- Stock Information
- Founded
- EWTX 2017
- PGRE 1978
- Country
- EWTX United States
- PGRE United States
- Employees
- EWTX N/A
- PGRE N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- PGRE Real Estate Investment Trusts
- Sector
- EWTX Health Care
- PGRE Real Estate
- Exchange
- EWTX Nasdaq
- PGRE Nasdaq
- Market Cap
- EWTX 1.5B
- PGRE 1.5B
- IPO Year
- EWTX 2021
- PGRE 2014
- Fundamental
- Price
- EWTX $14.63
- PGRE $6.34
- Analyst Decision
- EWTX Buy
- PGRE Hold
- Analyst Count
- EWTX 9
- PGRE 4
- Target Price
- EWTX $39.89
- PGRE $5.63
- AVG Volume (30 Days)
- EWTX 723.3K
- PGRE 3.1M
- Earning Date
- EWTX 08-07-2025
- PGRE 07-30-2025
- Dividend Yield
- EWTX N/A
- PGRE N/A
- EPS Growth
- EWTX N/A
- PGRE N/A
- EPS
- EWTX N/A
- PGRE N/A
- Revenue
- EWTX N/A
- PGRE $711,729,000.00
- Revenue This Year
- EWTX N/A
- PGRE $1.41
- Revenue Next Year
- EWTX N/A
- PGRE N/A
- P/E Ratio
- EWTX N/A
- PGRE N/A
- Revenue Growth
- EWTX N/A
- PGRE 49.28
- 52 Week Low
- EWTX $10.60
- PGRE $3.75
- 52 Week High
- EWTX $38.12
- PGRE $6.89
- Technical
- Relative Strength Index (RSI)
- EWTX 58.59
- PGRE 50.89
- Support Level
- EWTX $13.34
- PGRE $6.26
- Resistance Level
- EWTX $14.08
- PGRE $6.52
- Average True Range (ATR)
- EWTX 0.57
- PGRE 0.21
- MACD
- EWTX 0.16
- PGRE -0.04
- Stochastic Oscillator
- EWTX 98.60
- PGRE 36.93
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.